You are here
Experimental Drug Aids Patients With Hyperlipidemia
Compared with placebo, AMG 145 at doses of 70 mg, 105 mg, and 140 mg every 2 weeks reduced Lp(a) levels at 12 weeks by 18%, 32%, and 32%, respectively (P The effect of AMG 145 on Lp(a) levels was consistent regardless of patients’ age, sex, race, history of diabetes, and previous statin regimen. Patients with higher levels of Lp(a) at baseline had larger absolute reductions but comparatively smaller percentage reductions in Lp(a) with AMG 145 compared with patients who had lower baseline Lp(a) values.
In summary, AMG 145 significantly reduced Lp(a) by up to 32% in subjects with hypercholesterolemia who were receiving a statin.